AstraZeneca, with worldwide headquarters in Cambridge, UK, announced that it is consolidating some of its California staffers at The Cove at Oyster Point in South San Francisco.
Giving stimulants to kids with attention deficit hyperactivity disorder (ADHD) may not help them complete homework or get better grades, a small study suggests.
The Americas has become the first region in the world to be free of measles, following a 22-year vaccination drive against the disease which continues to infect tens of thousands of people globally, the Pan American Health Organization said.
Amgen’s multiple myeloma drug did not fare better than Takeda’s older therapy Velcade in a study involving patients who had not yet been treated for the disease.
Shares of Kite Pharma were up after the company’s CAR-T therapy KTE-C19 demonstrated a 39 percent response rate, including a complete response rate of one-third of patients with various forms of Non-Hodgkin’s Lymphoma after three months of treatment, the company announced.
Bristol-Myers Squibb will evaluate the use of its blockbuster immunotherapy Opdivo with an experimental drug from Nektar Therapeutics to treat multiple cancers.
After a strategic review of its portfolio after its acquisition of Baxalta, Shire has terminated two biosimilar deals: one with Momenta Pharmaceuticals and the other with Coherus Biosciences.
Sanofi SA said the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development of a Zika vaccine, as efforts to prevent the infection gather momentum.
There are 3 key facts life sciences companies need to know about real-time or near real-time medical claims data to support timely business decision-making.
Mylan NV faced questions about the profit on its EpiPen emergency allergy treatment, following a report that the company makes 60 percent more on the injector than it had told Congress.